Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.74 |
| ▸ | RARB | P10826 | 11/20 | 0.52 |
| ▸ | RARG | P13631 | 11/20 | 0.52 |
| ▸ | RXRG | P48443 | 10/20 | 0.52 |
| ▸ | RXRB | P28702 | 8/20 | 0.52 |
| ▸ | RARA | P10276 | 8/20 | 0.52 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219697 | 1.00 | RXRA (0.74) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL10399252 | 0.87 | RXRA (0.56) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL10399253 | 0.87 | RXRA (0.56) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL10739422 | 0.81 | RXRA (0.48) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL10739416 | 0.81 | RXRA (0.48) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL7224256 | 0.80 | RARB (0.72) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL7224258 | 0.80 | RARB (0.72) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL7219497 | 0.77 | RXRA (0.74) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL7220790 | 0.77 | ALDH1A1 (0.48) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL7219495 | 0.77 | RXRA (0.74) | RXRARARBRARGRXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627652-B1 | Treatment of diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid | ALLERGAN, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-5455265-A | For mammals; skin disorders, cancer, inflammatory disease, cardiovascular diorders, autoimmune diseases and others | ALLERGAN, INC. (US) | 1995-10-03 | — | — | US | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |